Pep19 may alter fat distribution without weight loss
MDSpire News
November 17, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

In a 90-day randomized trial of 56 adults with obesity, 10-mg Pep19 reduced the android-to-gynoid fat ratio compared with placebo, whereas 5 mg did not.
Pep19 did not significantly change body weight, BMI, total fat mass, or lean mass compared with placebo.
The 10-mg dose reduced abdominal skinfold thickness and was associated with lower HbA1c and HOMA-IR; fasting glucose remained unchanged.
Lipid profiles, inflammatory biomarkers, and blood pressure did not differ significantly among groups, and no treatment-related toxicologic signals were identified.
The small sample, 90-day follow-up, and nonsignificant absolute-scale analysis of the primary endpoint limit interpretation; larger, longer trials are needed.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: